In 2014, olaparib was approved as maintenance therapy for platinum-sensitive advanced ovarian cancer with germline mutations in DNA repair genes BRCA1/2 that are required for the homologous recombination (HR) pathway of double-strand break (DSB) repair. Here, BRCA1 is linked to ovarian cancer.